Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442501 in Pediatric Achondroplasia
2023-503677-37-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2023
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of SAR442501 in achondroplasia (ACH) and osteochondrodysplasia, sponsored by Sanofi. Primary endpoint: Number of participants with adverse events (AE), serious adverse events (SAE), and adverse events of special interest (AESI) during the treatment-emergent period. Started Sep 2023; status: completed.
02
Drugs
SAR442501
03
Conditions
achondroplasia (ACH)osteochondrodysplasia
Beyond the preview
Go deeper on 2023-503677-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503677-37-00.